Dear Attorney General Pam Bondi,
I have outlined three FCA cases that I have sent to multiple law firms. They have all declined to take these cases. I am therefore reaching out directly because I believe this requires federal attention.
I believe that you and President Donald Trump have what it takes to address these issues and help fix systemic problems in our medical system. I am willing to do whatever is necessary to assist.
I want to be transparent about my background. My first girlfriend’s father, Stephen Donohoe, is best friends with President Joe Biden, and I did vote for President Biden. Sidenote it really is true. At the same time, I also love President Trump, and I was a HUGE fan of The Apprentice when it aired. I mention this because I believe the issues raised here cross all political lines. This is not political. This is about protecting the United States, its healthcare system, and taxpayers.
What I am describing involves medical corporations taking advantage of CMS, Medicare, Medicaid, and the American public. This is a systemic issue that affects everyone.
I am particularly concerned that my alma mater, The Ohio State University, may be involved in practices where patients are routed through the James Cancer Hospital to justify oncological billing even when there is no cancer diagnosis. I was told this by two physicians, including REDACTED, MD, and Dr. Sen Siva, who is a chief medical officer. Both are based in Columbus, Ohio. I believe this warrants investigation.
Throughout my career, I have always prioritized patient care. I examine my patients thoroughly and treat all individuals equally regardless of race, background, or circumstances. I trained at The Ohio State University, completed residency at Riverside Methodist Hospital, and have served as an attending physician at institutions including the University of Chicago, Midwestern University, and Loyola University. I have always held myself to a high standard.
What I have observed in practice has been deeply concerning. These issues have been present since my training, but as an attending physician, I have now experienced direct consequences for raising concerns.
I have also observed potential disparities in pain management. At Select Specialty Hospitals, I observed situations where white patients were receiving IV pain medications such as Dilaudid while Black patients were not. When I added appropriate pain control for Black patients, those medications were later removed by other physicians when I was off service, and patients and families continued to report uncontrolled pain. This pattern is concerning and should be reviewed.
I am requesting that these matters be investigated. I am willing to provide testimony, documentation, and any supporting materials needed.
Sincerely,
Dr. Kalki Bommaraju, MD, MPH
ADDITIONAL STATEMENT
My concern is that the system may have become so corrupt that even private attorneys are unwilling to pursue clear cases of medical fraud. I do not understand why multiple law firms would decline matters of this magnitude unless there are external pressures or systemic influences, such as healthcare industry lobbying, that discourage these cases from being brought forward. I believe this issue itself warrants investigation.
I am also concerned that physicians are effectively intimidated into complying with improper practices. When applying for credentialing at new hospitals, physicians must rely on prior institutions for references and approvals. If a physician raises concerns or reports misconduct, prior employers can negatively impact credentialing, making it difficult or impossible to continue practicing. This creates a system where doctors are discouraged from speaking out.
After being terminated by MedOne Healthcare Partners after approximately three months for raising concerns about what I believed to be clear fraud and other unclear reasons, I felt obligated to take action and report these issues.
I also want to clarify my background. I was a salutatorian in high school, a National Merit Scholar, and received a full scholarship for undergraduate education with guaranteed admission into medical school. I later obtained a Master of Public Health through an NIH-supported program. I have trained and practiced at multiple institutions and have always maintained high standards in patient care.
I believe that when these institutions are contacted, there may be attempts to discredit me. I want to make clear that I am a highly trained and experienced physician raising concerns in good faith.
Finally, I respectfully request that these concerns be shared with appropriate federal leadership. If possible, I would appreciate that President Donald Trump personally be made aware of these matters, as I would welcome the opportunity to discuss these issues in person.
ADDITIONAL STATEMENT
I would also like to provide additional context regarding disparities in pain management that I have observed over the course of my training and practice.
During my medical training at The Ohio State University Medical Center and Riverside Methodist Hospital between 2003 and 2011, patients with sickle cell disease were consistently scrutinized regarding their requests for pain medication. They were frequently characterized as drug-seeking, and this perspective was emphasized by instructors during training.
When I later practiced as an attending physician in Chicago, my experience was markedly different. Sickle cell patients were treated with a higher level of trust regarding their pain. When a patient stated that a specific dose of medication such as 2 milligrams or 3 milligrams of Dilaudid every 3 hours was required to control their pain, that information was generally respected and incorporated into treatment plans unless it was clearly unsafe.
In contrast, in Ohio, I observed that sickle cell patients were routinely prescribed significantly lower doses, such as 0.5 milligrams or 1 milligram of Dilaudid every 3 hours, regardless of what the patient reported as necessary for adequate pain control. This pattern appeared consistent and did not seem to be individualized based on patient needs.
Given that sickle cell disease disproportionately affects Black patients, I am concerned that this may reflect a broader pattern of unequal treatment. I believe this issue warrants careful review to determine whether there are systemic disparities in pain management practices affecting specific patient populations.
I respectfully request that these concerns be evaluated as part of a broader review of patient care practices perhaps even jointly by the DOJ and ACLU.
Finally, I believe that if Donald Trump addresses this problem, many people would respect him for defending the interests of Black patients.
Sorry for so many messages.
ADDITIONAL STATEMENT
I also want to add important context regarding why the racial disparities I observed in Ohio are especially concerning to me.
The first place in Ohio that I lived after leaving the Chicagoland area, where I lived from ages 5 through 10, was Middletown, Ohio. I attended Vail Middle School there, which was an all-Black middle school, and I lived in a townhouse community that was mostly Black residents. Before that, I lived in a townhouse community in Grand Island, New York, near Niagara Falls, where most of the residents were minorities, and my next-door neighbor was Black. In Chicago, I worked primarily on the South Side for many years, and most of my patients were Black.
Because of that background, when I observed at Select Specialty Hospital in Victorian Village in Columbus, Ohio, that Black patients were not being given IV Dilaudid while white patients were, it was deeply disturbing to me. I observed specific patients where I added IV Dilaudid for Black patients because their pain was not being adequately treated. When I later went off service, those medications would be removed by other physicians, and the patients and family members would continue to complain about uncontrolled pain.
I believe this may represent a violation of the civil rights of Black patients in Ohio who are admitted to these facilities. I believe this issue should be investigated by appropriate authorities, including the Attorney General of the United States, because I have specific patients on whom this occurred at Select Specialty Hospital in Victorian Village in Columbus, Ohio.
I also mention Middletown, Ohio, because I would like these concerns to be brought to the attention of Vice President J.D. Vance. He is from Middletown, and so am I. We both also attended The Ohio State University. I believe he would be deeply concerned by what I was told in Columbus, Ohio, regarding The Ohio State University Medical Center.
Specifically, I was told by physicians in Columbus that Ohio State was routing patients through the James Cancer Hospital in ways that justified or facilitated oncological billing for patients who did not actually have cancer or an oncological condition. I was told that patients might be passed through the James Cancer Hospital, have notes or services associated with that facility, and then be transferred elsewhere, creating a billing advantage or reducing the likelihood of denial. I believe this practice should be thoroughly investigated.
I respectfully request that these concerns regarding Columbus, Ohio, Select Specialty Hospital, and The Ohio State University Medical Center be reviewed carefully and shared with appropriate federal leadership.
Sincerely,
Kalki Bommaraju MD MPH
3/27/2026
electronically signed
contact kalkidoc@gmail.com if u feel like u want to help
KB
